Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would 35 cent bid get interest as this PoS keeps diving, or would that be throwing more good money away on this old rotten garbage?
Over the past couple of years, I used to post on here and on Yhoo and the https://innv.forumactif.com and I was called a basher and even called a soft basher and was even banned from https://innv.forumactif.com.
Well, how do you feel about me now, that you've lost everything?
FYI, I've lost everything too, because I listened to you instead of going with my gut feeling.
I went from having $14,408 worth of stock, to $555 worth of stock, a $13,853 loss.
jb- look at it this way. Just think about those shareholders of AYTU. They are really going to lose in the long run. They get a company which spends $1.50 to get $1.00 in revs, they get Dr. Da, and they will get a reverse split within a year after the merger.
Just goes to show you what kind of a person Boyd is. Birds of a feather.
Someone posted a link through yahoo on see thru equity target price of .70... lol And said we made it! lol Thought that was funny.
This thing is just comical at this point. Lost alot of money here. Oh well. Moving on. Shame on me.
I have now lost 94.72% of my original investment, due to INNVs failed business model and reverse split. After the reverse split, my average price per share is $22.42. For my, INNV has went from $22.42 per share, down to $1.19 per share and Dr.Damaj won an award for best business man. It's amazing, how Batermere and Honeycomb have disappeared after so much pumping.
In general, small bio’s cause huge losses, 93.25% of them never get an FDA approved drug and they are riddled with pumps, dumps, secondary offerings and of course reverse splits.
I realize that INNV is not a biotech in the true sense of the word, it's more so a nutracutical, snake oil company.
Oops, almost back down to the pre-split share price!
Then, wash, rinse and repeat!
We're looking at another drastic and premature reverse split, or merger with another failure of a company, or file for bankruptcy.
All of which essentially mean the same thing, with the end result being bankruptcy, it's just a matter of what gets us there first!
All you guys hoped for Fluticare, well it's here but it's not here, sold one lot, then don't have enough money for a second lot, because Dr.D needs his 8 million, plus he got sued for 5 million.
If it looks like a turd, smells like a turd and squishes like a turd, it's Dr.Damaj.
Oh wait, let's nominate him for CEO of the year again, just because of his race!
Oops....LOL... Forward-Looking Statements
https://finance.yahoo.com/news/aytu-bioscience-announces-addition-tuzistra-130000204.html
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the effects of the business combination of Aytu and the Commercial Portfolio and the previously announced, but not yet consummated, merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu's existing operations, the failure to obtain the required votes of Innovus' shareholders or Aytu's shareholders to approve the Merger and related matters, the risk that a condition to closing of the Merger may not be satisfied, that either party may terminate the merger agreement or that the closing of the Merger might be delayed or not occur at all, the price per share utilized in the formula for the initial $8 million merger consideration in the Merger may not be reflective of the current market price of Aytu's common stock on the closing date, potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Just shows how bad the INNV deal is.
So AYTU is down 50% from merger offer price, so now the merger is worth $1.20 per share in AYTU stock and falling almost daily...
Sad... so sad...
Why do you think anyone would by those POS shares
No one will buy the shares, unless Dr.D pays investors for buying new shares.
No, they won't BK, Dr. D has a whole kitty full of brand new freshly printed shares to move before that could happen...
Do not be surprised, if INNV files for bankruptcy in December 2019. Also, even if the merger occurs, it's still a bad deal.
I wouldn't be surprised to see the "merger" canceled, as they probably are seeing what a POS this company really is....
Honeycomb, what's the latest? Where have you been? Do you still have any Innovus/Infamous shares?
Bate, where have you been? Did you sell all of your Innovus shares? What's the latest?
Naw, they are just one quarter away from profitability As Dr.D has always stated...
When Dr.D talks about "profitability" he means, that he's the only one who's making the profits!
LOL - Losses-REPORT-is-out! Lower-revenues-LARGER-LOSSES-.81/share-ouch!
INNV stock is at $2.65 to buy and $1.61 to sell, an immediate loss of $1.04, great job Dr.Damaj, you rock!!!
Dr.Damaj, please do the following...
Please merge the smaller, non-profitable Innovus with a larger, yet still unprofitable company!
Please be sure to have redundant and competing products!
After the merger, please get your large and bloated pay out first and never take good care of your investors!
Please increase the float of shares to 500 trillion!
Please do another reverse split!
Please don't ever restock Fluticare!
Please don't sell each product at a cost of $1.50 for a profit of $1 dollar, instead, sell each product at at cost of $2, for a profit of $1 dollar.
Please don't do anymore overly optimistic and fake conference calls where you sound like an overly-caffinated, hill-billy-auctioneer!
Please get another non-deserved business award for being a genius!
Thank you.
Where is jbdiver in all of this? He was also a major pumper, as well as Honeycomb.
So, you are saying that INNV was buying its' own products to produce revenue, but since they bought their own products, there wasn't a profit?
Or are you saying since it costed them $1.50 to sell $1 worth of product, that they aren't profitable?
Or are both statements accurate?
It won't do any good to beat up $INNV investors that were taken by this scam.... I finally caught on, when the "profits by the end of the year" showed that revenues were being bought and paid for, but there were no profits...
Well now, Shawn (if that really is your name) that's what happen when you pump and pump! The chickens have come home to roost in your bank account, or lack thereof!
Don't remember calling you a basher unless I was being sarcastic. I've been down on this POS for many years
Remember when I first started posting negatively about Innovus and you called me a basher?
What do you think about your logic now?
I bailed. If you stay, How much more are you willing to lose
Are you still invested or should I say tied up with Innovus? Or, did you sell out before or after the reverse split? Or, are you still partly invested/shackled?
Cool, congratulations on your loss, nice!
You do realize that the only reason why Damaj keeps getting nominated for CEO of the year, is due to extreme political correctness, meaning they are trying to fill a demographic, it's not based on good performance, so...
The only reason Damaj got chosen as CEO of the year, is because he's of Arabian/Pakistani decent.
Also, when he was nominated for the award, the obviously did
not take into account how he got the share price up, due to a disastrous reverse split.
Also, when Damaj talked in the article about surrounding yourself with good people and stay positive, what that really meant, is lie to a bunch of suck/retail investors, screw them over and hide behind the safe harbor act, so no justice can be had.
Also, Damaj gets paid millions for the merger and does not have money for another Fluticare batch, nor does he care about Fluticare, his customers, or his investors.
All Damaj cares about is his fat paycheck and golden parachute.
This is the same way that Obama won the Nobel Peace prize and even Obama himself has admitted that he doesn't know why he was was give the Nobel Peace prize.
I agree Shawn and I've lost about $13,000 dollars on Innovus. How much have you lost?
INNV doesn't have any money left to order. They have to pay Da's unjustified salary along with the other incapable team. The stock is being kept artificially high. This should be a 0.10-0.20 stock. When the merger is complete, AYTU will have to issue more stock then do another RS to afford to waste money on INNV product promotion.
This whole thing is one big scam to suck more money out of the suckers who invest in either company.
Wow, Fluticare is not available from the Innovus website, a 404 error is displayed when trying to order it and it's out of stock on Amazon with a message that it may or may not be back.
Innovus is big joke scam to investors and Dr.D keeps getting awards for being a great business man, which does not make any sense...
Hi, I looked at your signature, are you like that rapper, Snoopdog? Also, what does Eman time has arrived, mean?
Jb, others, with gratitude
want to spread it!
eman time has arrived!
best to everyone !
snupDAWGOled
Shawn,thanks,i was in innv at A dime just Wondering when rs happened SnupDawgoled
Don't believe they have done anything yet. Merger has to be approved by both companies shareholders.
Shawn,re-visiting innocuous,please, when did they split innv shares? And when will merger be finalized,new symbol etc, with thanks SnupDawgoled
Merging 2 POS companies isn't the same as adding 2 negative numbers to get a positive result It still ends up as a negative result Look who helped create this acquisition. Shall we say an INNV board member.
$AYTU is now down to $1.10/sh - thus making the "merger" worth that much less...
Still hanging around. Price on this POS is being kept artificially high
Everyone left, due to the terrible performance of Dr.D and Innovus.
So far, I've lost about $14,000 dollars in Innovus, but I have not sold anything and I won't ever get it back from Innovus or the dumb merger, or greedy and corrupt Dr.Damage.
Dont ever remember saying that but ok.
Followers
|
116
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
20617
|
Created
|
02/04/13
|
Type
|
Free
|
Moderators |
Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy Relief in the U.S. Press Release |11/14/2017
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (“OTC”) medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains the most prescribed nasal steroid active pharmaceutical ingredient (“API”) and form for nasal allergy relief over the last 7 years. The Company is launching FlutiCare™ in over 10,000 independent pharmacies, direct and through Amerisource Bergen and McKesson, via its Beyond Human® extensive print media platform and through its extensive online channels and distributors, including its own website, Amazon, and Walmart online stores. As a second phase of its launch, Innovus Pharma will launch FlutiCare™ to large retail stores.
FlutiCare™ will be available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare™ will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment and is the only one providing an monthly autoship plan.
“We are very excited to launch FlutiCare™ OTC and provide all patients with allergy relief,” stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare™ traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1,” he continued.
FlutiCare™ was approved by the U.S. Food and Drug Administration (“FDA”) for OTC availability through Innovus Pharma’s partner’s approved abbreviated new drug application (“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing Innovus Pharma product family, offering a burgeoning portfolio of non-prescription medicine and consumer care supplements to consumers.
FlutiCare™ becomes the Company’s second available allergy relief product along with AllerVarx™, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.
In addition, the Company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare™ and our upcoming saline nasal spray NasaVa™.
About FlutiCare™
FlutiCare™ is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms. FlutiCare™ can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens. Nasal allergy symptoms include, nasal congestion, runny nose, sneezing, itchy nose, etc.
** FlutiCare™ contains the nasal steroid API that is physician recommended and consumer preferred **
https://www.youtube.com/watch?v=fHQBewvDK6M
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
Business Summary:
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.
Bassam Damaj, Ph.D. President and Chief Executive Officer:
Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
President and Chief Executive Officer
Prior to joining Innovus Pharma, Bassam Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company where he was responsible for the approval of its lead drug Vitaros™, a treatment for erectile dysfunction. Damaj also signed multimillion-dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. He was also a Co-founder of Bio-Quant, Inc., serving as the Chief Executive Officer/Chief Scientific Officer and managing the board of directors from its inception in June 2000 until its 2009 acquisition by Apricus Biosciences. In addition, Damaj was the Founder/Chairman/President/Chief Executive Officer of R&D Healthcare, and the Co-Founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was partof the Scientific Advisory Board of MicroIslet, Inc. He authored Immunological Reagents and Solutions: A Laboratory Handbook (2000) and won a U.S. Congressional Award for the Anthrax Multiplex Diagnostic Test in 2003. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in Molecular Oncology at McGill University.
Executive Vice President, Corporate Development and General Counsel
In addition to his responsibilities as Executive Vice President and Corporate Development and General Counsel, Randy Berholtz is also the Secretary of the company. He was the founding partner of the Sorrento Valley Law Group and is the former Executive Vice President and General Counsel and Secretary of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company. Prior to that time, he was the Vice President, General Counsel and Secretary of ACON Laboratories, Inc., a group of Chinese and U.S. life sciences companies. He has also been the Chief Operating Officer and General Counsel of IngleWood Ventures, L.P., a life sciences venture capital company, and the Interim General Counsel and Secretary of Nanogen, Inc. (NASDAQ: NGEN), a genomics tools company. He has also been an attorney with the law firms, including Heller Ehrman LLP, Cooley LLP, Kirkpatrick & Lockhart LLP (now K&L Gates LLP) and Cravath, Swaine & Moore LLP. He has a Bachelor of Arts degree from Cornell University, a Master of Arts degree from Oxford University (he was a Rhodes Scholar), and a Juris Doctor degree from Yale Law School - where he was a Senior Editor of the Yale Law Journal - and an MBA from the University of San Diego School of Business.
Vice President, Chief Financial Officer
Ryan has served as our Vice President and Chief Financial Officer since April 27, 2018. From July 2013 to April 2018, he was the Chief Financial Officer and Chief Accounting Officer of Signature Analytics, an outsourced finance and accounting firm. From October 2003 to July 2013, he was an Audit Senior Manager with Grant Thornton LLP, a financial accounting firm. Mr. Selhorn has significant experience with venture financings, public equity offerings, public debt offerings, mergers and acquisitions, interaction with the SEC and PCAOB, and implementation and monitoring compliance with the requirements of the Sarbanes-Oxley Act. Additionally, Mr. Selhorn has participated in several financial due diligence processes for acquisitions and capital financings. Mr. Selhorn received his B.S. in Accounting and Finance from Georgetown University, McDonough School of Business, and he is a certified public accountant in California.
Vice President of Operations
Christopher Stella has served as our Vice President of Operations since June 2018. From February 2014 to June 2018 he was President and CEO of Stella Marketing Group, a specialty marketing firm supporting the natural products industry including major public and private health and beauty companies advertising through various direct-to-consumer channels. One of which, Innovus Pharmaceuticals, where he worked directly with management and helped the company exceed revenue targets in both 2017 and 2018. From September 2013 to February 2014, he worked at Nutraclick, a technology-driven health and wellness products company, where he developed the marketing campaigns for their four leading brands found in both major retail outlets such as GNC, Walmart and CVS and popular ecommerce platforms. Mr. Stella received his Bachelor of Economics from the University of Massachusetts (Suma Cum Laude) at Amherst with minors in both Chinese and Finance from the School.
Existing Product Lines @ Innovus Pharma:
https://innovuspharma.com/our-products/
PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals. |
DiabaSens™ is a patent-pending advanced, all-natural cream specifically formulated to increase nerve sensation and blood flow in men and women of all ages. Its proprietary blend of key ingredients has been clinically tested to increase sensation of the skin and improve blood flow where applied. DiabaSens™ was developed by top medical researchers and produced in a top-quality, cGMP-certified and FDA-registered laboratory environment under the most rigorously professional conditions. The positive benefits provided by the individual and combination ingredients in DiabaSens™ have been published in leading medical journals.
_____________________________________________________________________________________________________________________________________________________________________
r
http://www.recalmax.com/
http://www.urivarx.com/
UriVArx® Bladder Control and Function
http://www.myandroferti.com/ - (In a dozen CVS "pilot" stores)
https://www.myvesele.com/ - (Better SEX, WOW-Z'ers)
https://www.ooyess.bargains/
** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company
Products ship world-wide - support YOUR company
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |